Skip to main content

Hoffman Reid's Form 4 filing

Vor Biopharma Inc.VOR · filed Aug 29, 2025

Accession no.
0001415889-25-023318
Filed
Aug 29, 2025, 6:05 PM ET
Trade date
Aug 27-28, 2025
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 2 non-derivative transactions. Open-market sales total $2.85M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hoffman ReidCIK 000151933910% Owner
Reprogrammed Interchange LLCCIK 000205075510% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 27, 2025Common StockSSaleDisposed−611,647$2.01F1−$1,226,535.7337,690,918Direct
Aug 28, 2025Common StockSSaleDisposed−806,351$2.01F3−$1,621,975.0436,884,567Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

This transaction was executed in multiple trades at prices ranging from $1.99 to $2.10. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

F3

This transaction was executed in multiple trades at prices ranging from $1.95 to $2.075. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)